Quick Answer
Aligos Therapeutics, Inc. reported R&D Expense of $69.45 million for fiscal year 2025.
Aligos Therapeutics, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $69.45M | -1.2% |
| 2024 | $70.27M | -3.8% |
| 2023 | $73.04M | -14.1% |
| 2022 | $85.08M | -18.3% |
| 2021 | $104.15M | +30.4% |
| 2020 | $79.89M | +81.4% |
| 2019 | $44.04M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $23.94M | +42.7% | +71.3% |
| June 30, 2025 | $13.98M | -33.8% | -3.6% |
| March 31, 2025 | $14.50M | -11.4% | -13.5% |
| September 30, 2024 | $16.77M | +5.7% | -20.5% |
| June 30, 2024 | $21.10M | +25.7% | +28.9% |
| March 31, 2024 | $16.37M | -9.8% | +3.1% |
| September 30, 2023 | $15.87M | -10.8% | -5.4% |
| June 30, 2023 | $16.78M | +1.6% | -7.5% |
- Aligos Therapeutics, Inc. showed a decrease of -1.2% in R&D Expense compared to the prior fiscal year.
- Over the 2019–2025 period, Aligos Therapeutics, Inc.’s r&d expense has grown by 57.7% (from $44.04 million to $69.45 million).
- The most recent figure is from Aligos Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 5, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: